The neuronal ceroid-lipofuscinoses (NCL) market is experiencing steady growth, driven by increasing awareness of this group of rare, inherited neurodegenerative disorders. Advances in gene therapy, enzyme replacement therapies, and novel drug development have been key drivers of growth in the NCL market. Companies like BioMarin and Abeona Therapeutics are leading efforts to develop targeted treatments, particularly for the most severe forms of the disease. Regulatory support and orphan drug designations have also facilitated market expansion, as governments and healthcare agencies incentivize research in rare diseases. In addition, continued investment in R&D, along with collaborations between pharmaceutical companies and research institutions, is expected to propel the market forward.
